vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Zeta Global Holdings Corp. (ZETA). Click either name above to swap in a different company.
Zeta Global Holdings Corp. is the larger business by last-quarter revenue ($394.6M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.7%, a 9.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 25.4%). Zeta Global Holdings Corp. produced more free cash flow last quarter ($60.9M vs $29.1M). Over the past eight quarters, Zeta Global Holdings Corp.'s revenue compounded faster (42.3% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Zeta Global Holdings Corp. is an American marketing technology company which was founded in 2007. Zeta offers companies a suite of multichannel marketing tools focused on creating, maintaining, and monetizing customer relationships. The company went public on the New York Stock Exchange on June 10, 2021, at a US$1.7 billion valuation.
ANIP vs ZETA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $394.6M |
| Net Profit | $27.5M | $6.5M |
| Gross Margin | — | 59.5% |
| Operating Margin | 14.1% | 4.5% |
| Net Margin | 11.1% | 1.7% |
| Revenue YoY | 29.6% | 25.4% |
| Net Profit YoY | 367.5% | -57.1% |
| EPS (diluted) | $1.14 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $394.6M | ||
| Q3 25 | $227.8M | $337.2M | ||
| Q2 25 | $211.4M | $308.4M | ||
| Q1 25 | $197.1M | $264.4M | ||
| Q4 24 | $190.6M | $314.7M | ||
| Q3 24 | $148.3M | $268.3M | ||
| Q2 24 | $138.0M | $227.8M | ||
| Q1 24 | $137.4M | $194.9M |
| Q4 25 | $27.5M | $6.5M | ||
| Q3 25 | $26.6M | $-3.6M | ||
| Q2 25 | $8.5M | $-12.8M | ||
| Q1 25 | $15.7M | $-21.6M | ||
| Q4 24 | $-10.3M | $15.2M | ||
| Q3 24 | $-24.2M | $-17.4M | ||
| Q2 24 | $-2.3M | $-28.1M | ||
| Q1 24 | $18.2M | $-39.6M |
| Q4 25 | — | 59.5% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 62.1% | ||
| Q1 25 | — | 60.9% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.6% | ||
| Q2 24 | — | 60.0% | ||
| Q1 24 | — | 60.6% |
| Q4 25 | 14.1% | 4.5% | ||
| Q3 25 | 15.9% | 2.6% | ||
| Q2 25 | 6.6% | -1.7% | ||
| Q1 25 | 13.3% | -6.1% | ||
| Q4 24 | -2.3% | 2.2% | ||
| Q3 24 | -13.8% | -4.6% | ||
| Q2 24 | 3.7% | -11.7% | ||
| Q1 24 | 14.8% | -18.4% |
| Q4 25 | 11.1% | 1.7% | ||
| Q3 25 | 11.7% | -1.1% | ||
| Q2 25 | 4.0% | -4.2% | ||
| Q1 25 | 8.0% | -8.2% | ||
| Q4 24 | -5.4% | 4.8% | ||
| Q3 24 | -16.3% | -6.5% | ||
| Q2 24 | -1.7% | -12.3% | ||
| Q1 24 | 13.2% | -20.3% |
| Q4 25 | $1.14 | $0.04 | ||
| Q3 25 | $1.13 | $-0.02 | ||
| Q2 25 | $0.36 | $-0.06 | ||
| Q1 25 | $0.69 | $-0.10 | ||
| Q4 24 | $-0.45 | $0.10 | ||
| Q3 24 | $-1.27 | $-0.09 | ||
| Q2 24 | $-0.14 | $-0.16 | ||
| Q1 24 | $0.82 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $319.8M |
| Total DebtLower is stronger | — | $197.1M |
| Stockholders' EquityBook value | $540.7M | $804.6M |
| Total Assets | $1.4B | $1.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $319.8M | ||
| Q3 25 | $262.6M | $385.2M | ||
| Q2 25 | $217.8M | $365.3M | ||
| Q1 25 | $149.8M | $364.4M | ||
| Q4 24 | $144.9M | $366.2M | ||
| Q3 24 | $145.0M | $418.5M | ||
| Q2 24 | $240.1M | $154.7M | ||
| Q1 24 | $228.6M | $141.6M |
| Q4 25 | — | $197.1M | ||
| Q3 25 | — | $196.9M | ||
| Q2 25 | — | $196.7M | ||
| Q1 25 | — | $196.5M | ||
| Q4 24 | — | $196.3M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | — | $184.4M | ||
| Q1 24 | — | $184.2M |
| Q4 25 | $540.7M | $804.6M | ||
| Q3 25 | $505.8M | $689.2M | ||
| Q2 25 | $436.8M | $673.3M | ||
| Q1 25 | $418.6M | $676.6M | ||
| Q4 24 | $403.7M | $676.8M | ||
| Q3 24 | $405.9M | $474.9M | ||
| Q2 24 | $455.8M | $217.0M | ||
| Q1 24 | $452.0M | $191.6M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $869.1M | ||
| Q2 24 | $920.8M | $583.9M | ||
| Q1 24 | $914.5M | $550.3M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.96× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $64.1M |
| Free Cash FlowOCF − Capex | $29.1M | $60.9M |
| FCF MarginFCF / Revenue | 11.8% | 15.4% |
| Capex IntensityCapex / Revenue | 0.5% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 9.81× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $185.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $64.1M | ||
| Q3 25 | $44.1M | $57.9M | ||
| Q2 25 | $75.8M | $42.0M | ||
| Q1 25 | $35.0M | $34.8M | ||
| Q4 24 | $15.9M | $43.7M | ||
| Q3 24 | $12.5M | $34.4M | ||
| Q2 24 | $17.4M | $31.1M | ||
| Q1 24 | $18.3M | $24.7M |
| Q4 25 | $29.1M | $60.9M | ||
| Q3 25 | $38.0M | $52.4M | ||
| Q2 25 | $71.8M | $39.7M | ||
| Q1 25 | $32.5M | $32.1M | ||
| Q4 24 | $13.5M | $35.4M | ||
| Q3 24 | $7.7M | $29.5M | ||
| Q2 24 | $13.0M | $24.4M | ||
| Q1 24 | $13.7M | $18.9M |
| Q4 25 | 11.8% | 15.4% | ||
| Q3 25 | 16.7% | 15.6% | ||
| Q2 25 | 34.0% | 12.9% | ||
| Q1 25 | 16.5% | 12.1% | ||
| Q4 24 | 7.1% | 11.3% | ||
| Q3 24 | 5.2% | 11.0% | ||
| Q2 24 | 9.4% | 10.7% | ||
| Q1 24 | 10.0% | 9.7% |
| Q4 25 | 0.5% | 0.8% | ||
| Q3 25 | 2.7% | 1.6% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 1.3% | 2.6% | ||
| Q3 24 | 3.2% | 1.8% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | 3.0% |
| Q4 25 | 1.10× | 9.81× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ZETA
Segment breakdown not available.
